Introduction {#s1}
============

Diabetic kidney disease (DKD) is a major microvascular complication of diabetes mellitus and one of the leading factors of morbidity and mortality in diabetic patients ([@B38]). According to the latest statistical data, DKD is responsible for 40--50% of all cases of end-stage renal disease (ESRD) ([@B8]). To date, there is no curative therapeutic strategy for DKD; therefore, it is urgent to explore the underlying mechanism and develop specific and effective therapies. Currently, the major method for improving prognosis and alleviating symptoms is decreasing proteinuria, which is a major characteristic of DKD and the progression to ESRD, and improving renal function, which is reflected by decreased estimated glomerular filtration rate (eGFR) ([@B48]). One of the leading factors that accelerates the production of proteinuria is increased glomerular filtration membrane permeability for albumin and other proteins. The persistent dysfunction of the glomerular filtration barrier (GFB) is responsible for the progressive albuminuria of DKD patients under hyperglycemia conditions. Therefore, maintaining the structure and function of the microvasculature to reduce proteinuria in the early stage of DKD is indispensable for protecting renal function.

Autophagy is a key process in eukaryotic cellular recycling, and it addresses breakdown products and futile materials for cellular homeostasis under various stress conditions. This process is governed by upstream active factors, such as mTORC1, AMPK, ULK1, and mTORC1 ([@B11]). In recent years, it has been uncovered that altered autophagy in vascular endothelial cells, epithelial cells, pericytes, podocytes, and mesangial cells leads to imbalanced homeostasis and abnormal hemodynamics ([@B25]). A study showed that podocyte injury and severe proteinuria occur in diabetic mice with podocyte-specific autophagy deficiency and damaged lysosomes ([@B46]). It has been revealed that the pharmacological induction of autophagy has promising therapeutic potential to improve kidney function in diabetic patients ([@B25]).

Calcium dobesilate (calcium dihydroxy-2,5-benzenesulfonate, CaD), an artificially synthesized small molecule with antioxidative, anti-inflammatory, and anti-angiogenic properties, is now widely applied to the treatment of chronic vascular diseases, especially diabetic retinopathy. However, the specific mechanism is not yet clear. In addition, a number of studies have shown that CaD is a promising therapeutic strategy for microvascular disease not only in the retina but also in the kidney ([@B48]). Moreover, CaD has been confirmed to be capable of restoring altered vascular permeability under hyperglycemic conditions ([@B2]). It is known that the abnormal expression of vascular endothelial growth factor (VEGF) is closely related to increased vascular permeability. At present, VEGF is a therapeutic target for maintaining renal functionality ([@B1]). VEGF is primarily produced by podocytes and acts by binding to its receptor ([@B15]). It is clear that VEGF initiates and maintains the neovascularization process, which is injurious to the glomerular basement membrane (GBM) ([@B9]). CaD plays a key role in inhibiting VEGF not only by interfering with its receptor binding but also by regulating VEGF activity by specifically interfering with its interaction with glycoproteins ([@B18]). Lower levels of receptor binding lead to lower levels of downstream signal activation. Therefore, vascular permeability is restored. Abnormal autophagy and VEGF expression can lead to altered permeability, increased urinary albuminuria excretion, and abnormal renal function.

In the present study, our objective was to explore the underlying mechanism by which CaD restores autophagy in the kidneys of DKD mice. We also aimed to reveal the possible signaling pathway between VEGF and autophagy. We found that CaD has a significantly protective effect on reducing vascular permeability and decreasing proteinuria. CaD is a promising and prospective treatment for DKD and other microvascular diseases.

Materials and Methods {#s2}
=====================

Experimental Animals {#s2_1}
--------------------

Two types of rodent models were used in our experiments: obese mice with spontaneous diabetes (KK-Ay) ([@B35]; [@B47]) and high-fat diet- and streptozotocin-induced diabetic mice (HFD/STZ). 6-week-old male KK-Ay mice and C57BL/6 mice (25 ± 1 g) were obtained from Beijing HFK Bioscience Co., Ltd. (Beijing, China), and all mice were housed at 24 ± 2°C. All mice were given free access to chow and water. The study was approved by the ethical committee of Tianjin Medical University, and approval for the animal study was acquired from the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health as well as the guidelines of the Animal Welfare Act.

Experimental Procedures {#s2_2}
-----------------------

KK-Ay mice were fed an HFD for 14 days. Blood glucose and body weight increased significantly. Then, KK-Ay mice were randomly divided into two groups: the diabetic control group (KK-Ay, *n* = 15) and the CaD-treated group (KK-Ay+CaD, *n* = 15). As age-matched male C57BL/6 mice are commonly used as nondiabetic controls for KK-Ay mice, we randomly selected C57BL/6 mice (25 ± 1 g) as the blank control group (NK, normal control, *n* = 15). The mice in the KK-Ay+CaD group were treated intragastrically with CaD at a dose of 200 mg/(kg·d) ([@B31]; [@B43]; [@B45]) daily for 12 weeks. The CaD powder was dissolved in water at a concentration of 10%. The CaD powder was purchased from Ebewe Pharma Ges.m.b.H.Nfg.KG (A-4866 Unterach, Austria).

Meanwhile, 55 C57BL/6 mice (19 ± 1 g) were randomly divided into two groups: the standard diet group (NC, normal control, *n* = 15) and the HFD group (*n* = 40). The HFD consisted of 48.5% carbohydrate, 17.5% protein, and 17.9% fat. It was purchased from HFK Bio-Technology Co., Ltd. (Beijing, China). After 12 weeks, blood glucose levels and insulin resistance in the HFD group were measured by the intraperitoneal glucose tolerance test (IPGTT). Then, HFD mice were intraperitoneally injected with streptozotocin (STZ) at a dose of 30 mg/(kg·d) for seven consecutive days ([@B3]). Then, blood glucose levels were tested within 72 h. The successful modeling rate was not ideal. Thus, we continued the injection at the same dose for three more days. After 10 days of injection, the blood glucose of 30 mice exceeded 16.6 mmol/L ([@B44]), and those 30 mice were considered qualified models of diabetes. The 10 unsuccessful model mice were excluded. The 30 HFD/STZ-induced diabetic mice were randomly divided into two groups: the diabetic control group (HFD/STZ, *n* = 15) and the CaD treatment group (HFD/STZ+CaD, *n* = 15). The HFD/STZ+CaD group received CaD intragastrically at a dose of 200 mg/(kg·d) for 12 weeks. The control groups received vehicle at the same dose for the same amount of time.

Intraperitoneal Glucose Tolerance Test (IPGTT) {#s2_3}
----------------------------------------------

After being fed an HFD for 12 weeks, the HFD mice were fasted overnight for 12 h and peritoneally injected with glucose at a dose of 2 g/kg ([@B12]). The caudal vein blood glucose level was measured 0, 15, 30, 60, 90, and 120 min after the glucose load.

Biochemical Analysis {#s2_4}
--------------------

After 12 weeks of treatment with CaD or vehicle, the mice were sacrificed under anesthesia. Blood samples were collected from the retroorbital venous plexus, and urine samples were collected from specific metabolic cages. The blood and urine samples were analyzed for fasting blood glucose (FBG), urinary albumin/creatinine (ACR), total triglyceride (TG), total cholesterol (TC), alanine transaminase (ALT), aspartate transaminase (AST), and serum creatinine (Scr) levels with an automatic biochemistry analyzer (Roche). Based on FBG, UAE, and ACR levels, all mice were diagnosed with DKD.

Histopathological Examination {#s2_5}
-----------------------------

Kidney samples were immersed in 4% paraformaldehyde and embedded in paraffin, and cross-sections were prepared for hematoxylin/eosin (HE) staining, Masson staining, and periodic acid-Schiff (PAS) staining (Leagene Biotechnology, Beijing, China). 20--30 glomeruli in each animal were measured. The mean glomerular volume (MGV) was determined from the mean glomerular cross-sectional area (MGA) and calculated as:
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where ß = 1.38 is the shape coefficient for a sphere and *K* = 1.1 is the distribution coefficient ([@B30]). The mesangial matrix area (MMA) was defined as PAS-positive mesangial area in each glomerular tuft ([@B29]). Examination of the sections was performed under a microscope at a magnification of 400×, and all images were quantified with Image-Pro Plus 6.0 software.

Immunohistochemistry {#s2_6}
--------------------

The kidneys were immersed in 4% paraformaldehyde and embedded in paraffin. Kidney cross-sections were dewaxed heated for antigen retrieval, incubated with 3% H~2~O~2~ to block endogenous peroxidase activity and blocked with 1% BSA. Then, the sections were incubated at 4°C overnight with the following primary antibodies: anti-LC3 (B) (Cell Signaling Technology, 1:50), anti-P62/SQSTM1 (Abcam, 1:100), anti-nephrin (Abcam, 1:100), and anti-podocin (Abcam, 1:100). The sections were incubated with the relevant secondary antibodies, and the positive staining was visualized by staining with diaminobenzidine (DAB) and counterstaining with hematoxylin and examined under an electron microscope at a magnification of 400×. All images were quantified with Image-Pro Plus 6.0 software.

Western Blotting Analysis {#s2_7}
-------------------------

Kidney lysates were prepared with RIPA lysis buffer containing phenylmethanesulfonyl fluoride (PMSF) and phosphate inhibitor (100:1:1). Equal amounts of selected protein extract samples were loaded onto sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE) gels and transferred to polyvinylidene difluoride (PVDF) membranes (0.45 μm and 0.22 μm, Millipore, MA, USA). After being blocked for 2 h in 5% skim milk/TBST, the PVDF membranes were washed with Tris-buffered saline containing 0.1% Tween-20 (TBST) three times and incubated overnight at 4°C with different primary antibodies (anti-PI3K, 1:1,000; anti-p-PI3K, 1:1,000; anti-Akt, 1:1,000; anti-p-Akt, 1:1,000; anti-mTOR, 1:1,000; anti-p-mTOR, 1:1,000; anti-LC3, 1:500; anti-p62/SQSTM1, 1:1,000. anti-ATG5, 1:1,000; anti-beclin 1, 1:1,000; anti-VEGF, 1:1,000; anti-VEGFR2, 1:1,000; and anti-β-tubulin 1:2,000). The abovementioned primary antibodies were all obtained from Cell Signaling Technology (Danvers, MA, USA). Next, the PVDF membranes were washed with TBST three times and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (Cell Signaling Technology, Danvers, MA, USA) at room temperature for approximately 1 h. The immunoreactive of the bands was visualized by Bio-Rad Image Lab with an electrochemiluminescence system (ECL). The densitometric analysis of the protein bands was accomplished by ImageJ (NIH image software) and was normalized to relevant controls.

Statistical Analysis {#s2_8}
--------------------

The data are presented as the mean ± standard error of the mean (SEM), and the statistical analysis was carried out by one-way analysis of variance (ANOVA) for comparisons of more than three groups. A *P* value of 0.05 or less was considered significant. Graphical results were analyzed using GraphPad Prism 8 (GraphPad Software, Inc., La Jolla, CA, USA). Statistical and data analyses were performed with IBM SPSS software 20.0 (SPSS, Chicago, IL, USA).

Results {#s3}
=======

Calcium Dobesilate Decreased Albuminuria in KK-Ay and HFD/STZ Mice {#s3_1}
------------------------------------------------------------------

The IPGTT was performed before the administration of CaD. The results indicated that the glucose tolerance is impaired in KK-Ay and HFD-induced diabetic mice ([**Table 1**](#T1){ref-type="table"}). To estimate the therapeutic effect of CaD, we measured the body weight (BW), FBG levels, kidney weight to body weight (KW/BW), urinary albumin excretion (UAE), serum creatinine (Scr) levels, urinary albumin/creatinine (ACR) levels, TG levels, TC levels, and alanine aminotransferase (ALT) levels of all groups after 12 weeks of treatment with CaD (*n* = 15) or vehicle (*n* = 15) ([**Tables 2**](#T2){ref-type="table"} and [**3**](#T3){ref-type="table"}, [**Supplementary Materials**](#SM1){ref-type="supplementary-material"}). [**Figure 1A**](#f1){ref-type="fig"} shows the BW and blood glucose levels during 12 weeks of CaD or vehicle treatment. UAE levels and KW/BW in DKD were significantly decreased after CaD treatment. BW, FBG levels, KW/BW, ALT levels, TG levels, TC levels, and Scr levels were not significantly different before and after CaD treatment. Scr levels showed were not significantly different between DKD mice and normal control mice.

###### 

Results of the intraperitoneal glucose tolerance test (IPGTT) in NC- and HFD-induced diabetic mice.

  Glucose (mmol/L)   NC             HFD
  ------------------ -------------- ----------------
  0 min              6.73 ± 2.43    8.98 ± 2.92
  15 min             21.30 ± 6.50   25.2 ± 7.30
  30 min             18.17 ± 7.17   31.8 ± 4.20\*
  60 min             11.95 ± 4.95   27.83 ± 8.17\*
  90 min             11.10 ± 4.10   22.92 ± 5.72\*
  120 min            9.02 ± 3.12    19.97 ± 6.23\*

NC, normal control, n = 15; HFD, high-fat diet, n = 15; \* p \< 0.05 vs. respective control.

###### 

Results of the biochemical analysis of obese mice with spontaneous diabetes (KK-Ay) mice.

                  NK             KK-Ay            KK-Ay+CaD
  --------------- -------------- ---------------- -----------------
  BW (g)          27.35 ± 1.37   44.23 ± 1.22\*   43.22 ± 1.20\*
  FBG (mmol/L)    6.57 ± 1.81    30.30 ± 2.06\*   30.90 ± 2.32\*
  KW/BW (mg/g)    4.47 ± 0.57    5.94 ± 0.26\*    5.31 ± 0.33^\#^
  UAE (µg/24 h)   0.26 ± 0.10    11.23 ± 2.90\*   7.11 ± 1.02^\#^
  ALT (U/L)       21.80 ± 7.80   60.66 ± 19.01    62.33 ± 17.09\*
  TG (mmol/L)     1.97 ± 0.35    3.42 ± 0.77\*    3.16 ± 1.91\*
  TC (mmol/L)     1.20 ± 0.79    3.98 ± 2.1\*     3.42 ± 1.56
  Scr (mmol/L)    16.60 ± 9.09   16.58 ± 4.66     18.21 ± 4.22

BW, body weight; FBG, fasting blood glucose; KW/BW, kidney weight to body weight; UAE, urinary albumin excretion; ALT, alanine aminotransferase; TG, total triglycerides; TC, total cholesterol; Scr, serum creatinine; NK, normal control, n = 15; KK-Ay, n = 15; CaD, n = 15, calcium dobesilate. \*p \< 0.05 vs. NK group; ^\#^p \< 0.05 vs. KK-Ay group.

###### 

Results of the biochemical analysis of HFD/streptozotocin (STZ)-induced diabetic mice.

                  NC             HFD/STZ          HFD/STZ+CaD
  --------------- -------------- ---------------- -----------------
  BW (g)          23.49 ± 1.78   28.37 ± 2.07\*   26.61 ± 1.37\*
  FBG (mmol/L)    6.37 ± 1.44    20.51 ± 3.44\*   19.90 ± 5.33\*
  KW/BW (mg/g)    6.19 ± 0.51    7.79 ± 0.51\*    6.41 ± 0.35^\#^
  UAE (µg/24 h)   0.01 ± 0.01    2.13 ± 0.30\*    0.37 ± 0.31^\#^
  ALT (U/L)       23.81 ± 8.79   49.20 ± 2.10\*   52.49 ± 3.01\*
  TG (mmol/L)     0.67 ± 0.31    3.13 ± 0.08\*    3.04 ± 0.13\*
  TC (mmol/L)     1.49 ± 0.29    3.92 ± 1.15\*    3.99 ± 0.80\*
  Scr (mmol/L)    11.51 ± 1.62   13.10 ± 3.01     12.79 ± 2.45

BW, body weight; FBG, fasting blood glucose; KW/BW, kidney weight to body weight; UAE, urinary albumin excretion; ALT, alanine aminotransferase; TG, total triglycerides; TC, total cholesterol; Scr, serum creatinine; NC, normal control, n = 15; HFD/STZ, high-fat diet- and streptozotocin-treated, n = 15; CaD, calcium dobesilate, n = 15. \*p \< 0.05 vs. NC group; ^\#^p \< 0.05 vs. HFD/STZ group.

![Calcium dobesilate (CaD) restored hyperglycemia-induced renal histological changes. **(A)** Body weight and blood glucose measured after 12 weeks of CaD treatment. **(B)** The measurement of kidney samples of the mice compared to unified size markers. HE, PAS, and Masson staining of kidney samples. **(C)** The results of MMA, MGV, and Masson staining analysis. **(D, E)** The immunohistochemical quantification and analysis of nephrin and podocin in kidney samples. Original magnification of 400×. The scale bars in the right lower corner represent 100 µm. The error bars represent the SEM. The arrows indicate deposited glomerular mesangial matrix in the PAS-stained tissue, glomerular and tubulointerstitial fibrosis in Masson-stained tissue, and positive staining in immunohistochemical-stained tissue. HE, hematoxylin/eosin; PAS, periodic acid-Schiff; MGA, mean glomerular area; MGV, mean glomerular volume, MGV = β/K x (MGA)^3/2^; NK/NC, normal control, *n* = 15; STZ, high-fat diet- and streptozotocin-treated, *n* = 15; CaD, calcium dobesilate, *n* = 15. \**p* \< 0.05 *vs*. control group; ^\#^ *p* \< 0.05 *vs*. DKD (diabetic kidney disease) group.](fphar-10-00886-g001){#f1}

Calcium Dobesilate Attenuated Renal Histological Destruction {#s3_2}
------------------------------------------------------------

After 12 weeks of CaD treatment, the mice were sacrificed, and kidney samples were harvested. The size of the kidneys of KK-Ay (*n* = 15) and HFD/STZ (*n* = 15) mice was apparently larger than that of the kidneys of the NK (*n* = 15) and NC (*n* = 15) mice. The sizes were restored in the KK-Ay+CaD (*n* = 15) and HFD/STZ+CaD (*n* = 14) mice ([**Figures 1B, C**](#f1){ref-type="fig"}). Meanwhile, HE, PAS, and Masson staining were performed to determine the MGA, MGV, MMA, and relative fibrotic area to measure the glomerular volume and evaluate kidney structure. The results showed that the MGA, MGV, MMA, and relative fibrotic area were increased in DKD and decreased after CaD treatment. These results indicate that CaD is capable of attenuating glomerular enlargement, glomerular MMA expansion, and glomerular and tubular fibrosis in DKD mice.

Hyperglycemia-Induced Glomerular Filtration Membrane Injuries Were Restored by Calcium Dobesilate {#s3_3}
-------------------------------------------------------------------------------------------------

To determine the effect of CaD on the glomerular filtration membrane, the glomerular-specific indicators nephrin and podocin were detected by immunohistochemistry ([**Figures 1D, E**](#f1){ref-type="fig"}). In KK-Ay and HFD/STZ mice, the expression of nephrin and podocin was significantly lower than that in C57BL/6 mice, indicating more filtration membrane damage. CaD rescues the changes in DKD mice. The results confirmed the protective effect of CaD on the glomerulus. The results indicate that CaD is capable of reducing albuminuria and protecting against renal histological changes.

Calcium Dobesilate Restored Autophagy in the Kidneys of KK-Ay and HFD/STZ Mice {#s3_4}
------------------------------------------------------------------------------

We analyzed the abundance of autophagy-related proteins in kidney lysates by western blotting and immunohistochemistry. As shown in [**Figures 2A, B**](#f2){ref-type="fig"}, the protein expression levels of LC3 II, Atg5, and beclin 1 were significantly decreased in the DKD groups compared with the respective control groups and significantly increased after CaD treatment. Moreover, the protein expression level of p62 was significantly increased in the DKD groups and decreased in the CaD treatment groups ([**Figures 2A, B**](#f2){ref-type="fig"}). According to the immunohistochemistry results, the expression of LC3 was significantly decreased in the DKD groups compared with the control groups and restored in the CaD treatment groups. Meanwhile, the expression of p62 in DKD decreased after CaD treatment ([**Figures 2C, D**](#f2){ref-type="fig"}). The results suggest that CaD is effective at restoring autophagy in DKD.

![Calcium dobesilate upregulated autophagy in DKD mice. **(A)** Representative western blot analysis of Beclin 1, Atg5, p62, and LC3 in mice. **(B)** The densitometric results of Beclin 1, Atg5, P62, and LC3 expression, as determined by western blotting. The error bars represent the SEM. **(C, D)** The immunohistochemical quantification and analysis of LC3 and p62 in kidney samples. The scale bars in the right lower corner represent 100 µm. The arrows indicate positive staining. NK/NC: normal control, *n* = 15; STZ, high-fat diet- and streptozotocin-treated, *n* = 15; CaD: calcium dobesilate, *n* = 15. \**p* \< 0.05 *vs*. control group; ^\#^ *p* \< 0.05 *vs*. DKD group.](fphar-10-00886-g002){#f2}

Calcium Dobesilate Decreased VEGF and Downregulated VEGFR2 {#s3_5}
----------------------------------------------------------

According to the western blotting analysis shown in [**Figure 3**](#f3){ref-type="fig"}, the protein expression levels of VEGF and VEGFR2 were significantly increased in the KK-Ay and HFD/STZ groups compared with the control group. After CaD treatment, the expression levels of VEGF and VEGFR2 were restored. The results indicate that CaD is capable of restoring VEGF changes and maintaining vascular construction and function.

![Calcium dobesilate decreased VEGF and VEGFR2. **(A)** Western blots of VEGF for each group. **(B)** Densitometric results of VEGF as determined by western blot. Error bars represent SEM. **(C)** Western blots of VEGFR2 for each group. **(D)** The densitometric results of VEGFR2 expression, as determined by western blot. The error bars represent the SEM. VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2; NK/NC: normal control, *n* = 15; STZ, high-fat diet- and streptozotocin-treated, *n* = 15; CaD: calcium dobesilate, *n* = 15. \**p* \< 0.05 *vs*. control group; ^\#^ *p* \< 0.05 *vs*. DKD group.](fphar-10-00886-g003){#f3}

Calcium Dobesilate Inactivated the PI3K/AKT/mTOR Signaling Pathway *via* Inhibiting the Phosphorylation of Proteins {#s3_6}
-------------------------------------------------------------------------------------------------------------------

To confirm the underlying mechanism of improved autophagy in CaD, we evaluated the activation of the PI3K/AKT/mTOR signaling pathway. As one of the downstream signaling pathways of VEGF/VEGFR2, PI3K/AKT, like VEGF/VEGFR2, is active under hyperglycemic conditions. According to the western blot results, the relative expression of p-PI3K/t-PI3K, p-AKT/t-AKT, and p-mTOR/t-AKT was increased in the DKD groups and decreased in the CaD treatment groups (KK-Ay+CaD and HFD/STZ+CaD) ([**Figures 4A--F**](#f4){ref-type="fig"}). These results suggest that CaD inhibits the PI3K/AKT/mTOR pathway. Finally, we constructed a hypothetical pathway of CaD intervention ([**Figure 5**](#f5){ref-type="fig"}).

![Calcium dobesilate inhibited the downstream of VEGF/VEGFR2/PI3K/AKT/mTOR signaling pathway. **(A)** Representative western blots of p-PI3K and t-PI3K. **(B)** The densitometric results of p-PI3K and t-PI3K expression, as determined by western blot. The error bars represent the SEM. **(C)** Representative western blots of p-Akt and t-Akt. **(D)** The densitometric results of p-Akt and t-Akt expression, as determined by western blot. The error bars represent the SEM. **(E)** Representative western blots of p-mTOR and t-mTOR. **(F)** The densitometric results of p-mTOR and t-mTOR expression, as determined by western blot. The error bars represent the SEM. p, phosphorylated; t, total; NK/NC: normal control, *n* = 15; STZ, high-fat diet- and streptozotocin-treated, *n* = 15; CaD: calcium dobesilate, *n* = 15. \**p* \< 0.05 *vs*. control group; ^\#^ *p* \< 0.05 *vs*. DKD group.](fphar-10-00886-g004){#f4}

![Hypothetical pathway between autophagy and VEGF. A presentation of the interplay between the implicated signaling factors under hyperglycemia and CaD therapy conditions. VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2; Tyr-P, phosphorylated tyrosinase; CaD, calcium dobesilate.](fphar-10-00886-g005){#f5}

Discussion {#s4}
==========

In our study, we first demonstrated the ability of CaD to decrease albuminuria by restoring autophagy through the VEGF/PI3K/Akt/mTOR pathway in KK-Ay mice and HFD/STZ-induced diabetic mice. In diabetic murine models, CaD reduced KW/BW and UAE levels without altering BW, or ALT, Scr, TG, or TC levels. The results indicate that CaD may not be a hypoglycemic drug but may be useful for reducing albuminuria. It has been confirmed that CaD is protective for renal function and is has a potential clinical application for delaying DKD progression.

Two diabetic models were used in our study: obese mice with spontaneous diabetes (KK-Ay) and HFD/STZ. An ideal model of diabetic nephropathy should exhibit progressive albuminuria, abnormal renal function, and characteristic histological changes in the glomeruli and tubulointerstitial lesions ([@B3]; [@B12]; [@B44]). KK-Ay mice are a typical animal model of the early to moderate stages of type 2 diabetic nephropathy ([@B22]).

Additionally, to exclude the specificity of animal models and make the research more convincing, we also used HFD/STZ-induced diabetic mice. HFD feeding is known to induce various systemic metabolic alterations, including obesity, insulin resistance, hyperglycemia, and abnormal lipid metabolism. Systematic lipid overload and glycemia may explain renal injury ([@B29]; [@B16]). STZ is known for its toxicity, especially on islet β cells. According to our results, renal injury, including glomerular hypertrophy, mesangial matrix expansion, and the thickening of the glomerular and tubular basement membrane, are more severe in HFD/STZ mice than in KK-Ay mice. Hyperglycemia-induced oxidative stress and STZ toxicity may account for the results.

On the basis of the results of albuminuria levels, the GMV, the MMA, and IH for nephrin and podocin, CaD significantly restored glomerular, mesangial, and tubular lesions. Thus, we hypothesized that CaD is angioprotective and is a promising candidate for the treatment of chronic kidney diseases.

Albuminuria is usually considered to be representative of an injured filtration membrane and decreased renal function ([@B34]). The pathophysiology includes altered hemodynamics, ischemia, inflammation, overactive RAAS, and oxidative stress. Recent studies have shown that the novel pathogenesis of DKD includes genetic modification, epigenetic regulation, decreased podocyte autophagy, and mitochondrial dysfunction ([@B26]). In conclusion, renal injury is caused by various factors. Thus, we aimed to determine the alterations in autophagy that occur during DKD progression and to determine whether CaD alters autophagy. The quantitative level of autophagy can be determined by the gray values of LC3 II/LC3 I, p62/β-tubulin, beclin 1/β-tubulin, and ATG5/β-tubulin bands ([@B17]; [@B32]; [@B42]) ([**Figure 2**](#f2){ref-type="fig"}). Our results confirm this conjecture. CaD significantly restored autophagy in DKD.

CaD is applied for the treatment of diabetic microvascular diseases, especially for diabetic retinopathy because of its angioprotective properties ([@B40]; [@B4]; [@B5]; [@B23]). Clinical studies have noted that alprostadil combined with CaD is widely applied for the treatment of renal disease ([@B33]), and CaD has been confirmed to be effective in maintaining the construction of the vascular endothelium and enhancing renal function ([@B20]). However, the specific mechanism is not yet clear. One recent study demonstrated that ferulic acid can circumvent oxidative stress-mediated renal cell damage by regulating autophagy ([@B24]; [@B6]). In our study, we demonstrated for the first time that CaD is effective in restoring autophagy in the kidneys of KK-Ay and HFD/STZ-induced diabetic mice. The restored autophagy may account for the decreased albuminuria level in DKD mice after CaD treatment through repairing the filtration membranes.

In addition, VEGF disturbance is also a major factor that results in renal injury by inducing angiogenesis and vascular permeability. VEGF is overexpressed under stress conditions such as hyperglycemia. Excessive VEGF participates in the pathogenesis of endothelial cell dysfunction. VEGF acts by phosphorylating tyrosine residues of the VEGF receptor and regulates incomputable downstream effectors by cooperating with compensatory signaling pathways ([@B19]). VEGFR1 is primarily involved in macrophage immigration and tumor angiogenesis. VEGFR2 is mainly expressed in the endothelium and participates in the regulation of endothelial cell performance. VEGFR3 is mainly involved in lymphangiogenesis ([@B14]; [@B7]).

Most of the cellular actions of VEGF in endothelial cells (e.g., the regulation of vascular permeability and the fenestration of endothelial cells) are predominantly regulated by VEGFR2 ([@B36]; [@B27]), and some studies have demonstrated that VEGF promotes eNOS phosphorylation *via* VEGFR2 in GENCs, resulting in an enhanced generation of nitric oxide ([@B13]). In summary, overexpressed VEGF is harmful for maintaining the structure of glomerular filtration barriers. In our present study, CaD significantly reduced the expression of VEGF and downregulated VEGFR2. Simultaneously, CaD restored filtration membrane injury markers (nephrin and podocin) and albuminuria levels. Therefore, we assume that the alleviation of renal injuries by CaD may have been due to reduced VEGF action. In other words, the angioprotective effect of CaD was confirmed.

The VEGF family mainly includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placenta growth factor (PIGF). VEGF-A binds both VEGFR1 and VEGFR2, whereas VEGF-B and PlGF bind only VEGFR1 ([@B28]; [@B10]; [@B41]). Activated VEGF-C/D bind and activate VEGFR2 in addition to VEGFR3 ([@B21]). Among the members of the VEGF family, VEGF-A plays a principal role in regulating vascular permeability and producing eNOS ([@B39]; [@B18]). We did not determine which ligands are involved in the alleviation of autophagy and renal injury by CaD in this study. Previous studies have shown that CaD acts as a heparin antagonist within the binding site and changes the three-dimensional structure of the growth factor at its receptor-recognizing site. As a result, the receptor-growth factor signaling complex is dissociated ([@B18]). In other words, CaD inhibits the binding of VEGF to heparin sulfates, thereby reducing the affinity of the VEGF/heparin sulfate complex for its receptor-binding sites.

While the effect of CaD on downregulating the activation of VEGF/VEGFR2 and restoring autophagy was confirmed, the specific mechanism is still unclear. In our study, we demonstrated that one of the possible pathways, the PI3K/Akt/mTOR pathway, was affected by CaD. Three main downstream pathways of VEGF/VEGFR2 exist: the JAK/STAT, MEK/ERK, and PI3K/AKT pathways. It has been demonstrated that phosphoinositide 3-kinase (PI3K) is induced by VEGF/VEGFR2, which augments PI3K activation by phosphorylation. VEGF also activates the AKT pathway in a PI3K-dependent manner ([@B37]; [@B13]). In our study, phosphorylated PI3K and AKT were significantly decreased after CaD treatment in KK-Ay and HFD/STZ-induced diabetic mice. As one of the downstream effectors of PI3K/AKT, mTOR is closely related to autophagy ([@B49]; [@B11]).

The primary signaling pathways that regulate autophagy include the mTOR, AMP-activated protein kinase (AMPK), and sirtuin (SIRT) pathways. We examined changes in AMPK phosphorylation before and after CaD treatment in DKD. There were no significant differences. Thus, we concluded that CaD rarely acts on the AMPK signaling pathway. mTOR phosphorylation decreased after CaD treatment in KK-Ay and HFD/STZ-induced diabetic mice. Thus, we concluded that CaD may regulate autophagy in DKD by inhibiting the PI3K/AKT/mTOR pathway, which is a downstream pathway of VEGFR2. However, there may be more links between VEGF and autophagy, and further research is required.

In conclusion, the angioprotective and autophagy-restoring effects of CaD were demonstrated in our study. Currently, CaD is mainly used for the treatment of diabetic retinopathy because it is effective in maintaining blood-retinal barrier integrity and reducing the permeability of the retina ([@B4]), which is possibly associated with autophagy. According to those properties, CaD is a very promising candidate for treating other types of autophagy-related organ damage and complications of vascular injury.
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